Bruno Pougault: Pregnancy and Thrombosis – Balancing Evolutionary Protection Against Clinical Risk
Bruno Pougault, Global Marketing Hemostasis Product Manager at HORIBA, shared on LinkedIn:
“Pregnancy and Thrombosis: Balancing Evolutionary Protection Against Clinical Risk
Why does pregnancy multiply a patient’s risk of Venous Thromboembolism (VTE) by 4 to 5 times?
From a physiological standpoint, it is a masterclass in evolutionary survival.
To protect the mother from lethal hemorrhage during placental delivery, the female body enters a state of profound hypercoagulability.
However, this protective mechanism pushes the hemostatic curve to a razor-thin edge, fulfilling all three pillars of Virchow’s Triad:
- Hypercoagulability: A systemic shift favoring clotting, driven by an increase in procoagulant factors (Fibrinogen, FVIII, VWF) paired with a physiological decline in natural anticoagulants like Protein S.
- Stasis: Mechanical compression of the inferior vena cava and pelvic veins by the gravid uterus severely impedes lower extremity venous return.
- Endothelial Alterations: Micro-vascular stress induced by rapid hemodynamic fluctuations during gestation and delivery.
The clinical stakes are high, and the window of maximum vulnerability is counterintuitive: the risk peaks not during the third trimester, but during the first 6 weeks of the postpartum period.
Evaluating underlying thrombophilia (such as Factor V Leiden, Prothrombin G20210A mutations, or Antiphospholipid Syndrome) without being misled by normal, pregnancy-induced biochemical baselines remains one of the most delicate challenges in laboratory medicine today.
Bridging Laboratory Insights and Bedside Decisions
Because this balance between life-saving hemostasis and life-threatening thrombosis remains a critical puzzle, it will be a focal point of global clinical discussion this summer.
The ISTH 2026 Congress (International Society on Thrombosis and Haemostasis), taking place in Paris from July 11–15, 2026, is dedicating multiple specialized sessions to
Hemostasis and Women’s Health.
Top global experts will present the latest clinical trials, long-term safety data on low-molecular-weight heparin (LMWH) prophylaxis, and emerging molecular biomarkers for early risk stratification.
If you are attending ISTH2026, these sessions are unmissable for anyone looking to refine their clinical protocols in obstetric hematology.
Let’s advance the science of maternal health together.
See you in Paris!”
Find more posts featuring Bruno Pougault on Hemostasis Today.
-
Jun 29, 2026, 15:17Heghine Khachatryan: Hemostasis at the Crossroads of Thrombosis and Bleeding
-
Jun 29, 2026, 15:07Tomaz Crochemore: From Bleeding to Thrombosis – The Era of Precision Hemostatic Medicine Has Arrived
-
Jun 29, 2026, 14:51Pete Stibbs: Building a Successful Venous Thrombectomy Practice
-
Jun 29, 2026, 13:32Omid Seidizadeh: The Full VWD Session from EHA 2026 Is Now Available to Watch
-
Jun 29, 2026, 13:22Cheryl Carcel: Make The Stroke Research More Inclusive for Women, Take The Survey
-
Jun 29, 2026, 13:18Bianca Rocca: New Expert Opinion On the Evolving Debate on Factor XI as a Therapeutic Target
-
Jun 29, 2026, 13:06Francisco Chacón-Lozsán: Intermittent Hemodialysis in the ICU Should not be Monitored Only by ‘Session Completed’
-
Jun 29, 2026, 13:01Edward Lee Carter: Exploring Anticoagulation Paradox
-
Jun 29, 2026, 12:55Salvatore Massimo Petrina: When is it Truly Safe to Stop Anticoagulation after AF Ablation?